Ratings Coherus BioSciences, Inc.

Equities

CHRS

US19249H1032

Real-time Estimate Cboe BZX Other stock markets 10:16:00 30/04/2024 pm IST			5-day change	1st Jan Change
1.985 ^USD	-4.11%		-8.72%	-40.24%

24/04	Coherus BioSciences, Inc. Announces Presentation of Clinical Data for CHS-114 at 2024 American Society of Clinical Oncology Annual Meeting	CI
20/03	HC Wainwright Adjusts Coherus BioSciences' Price Target to $11 From $13, Keeps Buy Rating	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
For the past twelve months, EPS forecast has been revised upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

Low profitability weakens the company.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
COHERUS BIOSCIENCES, INC.	-40.24%	235M	C-
VERTEX PHARMACEUTICALS INCORPORATED	-3.00%	102B	B+
REGENERON PHARMACEUTICALS, INC.	+1.85%	96.29B	B+
ARGENX SE	+2.13%	22.18B	B
BIONTECH SE	-15.53%	21.2B	B+
GENMAB A/S	-9.21%	18.31B	A-
WUXI APPTEC CO., LTD.	-39.98%	17.38B	A-
BEIGENE, LTD.	-15.72%	16.36B	B
NEUROCRINE BIOSCIENCES, INC.	+5.31%	13.97B	C+
SAREPTA THERAPEUTICS, INC.	+32.40%	12.17B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes